Stockscreener 앱 받기
5.72
2.05%
-0.12
시간 외 거래:
5.70
-0.02
-0.35%
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
Did Jim Cramer Nail All These 9 Stock Predictions? - Insider Monkey
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? - Insider Monkey
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - Bluefield Daily Telegraph
Why Biohaven Stock Plummeted by More Than 15% Today - The Motley Fool
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Recursion (RXRX) to Reveal Promising Data on REC-4881 for FAP Tr - GuruFocus
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know - MSN
Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal - Yahoo Finance
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy? - Yahoo Finance
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - MSN
Recursion Pharmaceuticals Licenses HealthVerity's Real-World Data - marketscreener.com
Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data - marketscreener.com
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - marketscreener.com
Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA” - MSN
Why Recursion Pharmaceuticals, Inc. (RXRX) Surged On Friday? - MSN
Tech Firms Dominate Monday’s 10 Worst Performers - Insider Monkey
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - Yahoo Finance
Jim Cramer Hints at a Bigger Agenda Behind Tariffs and Breaks Down These 7 Stocks - Insider Monkey
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Why Recursion Pharmaceuticals Inc. (RXRX) Soared Last Week? - MSN
Recursion Pharma (RXRX) Stock Climbs Amid FDA Shift In Testing R - GuruFocus
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today - MSN
Biotech Revolution: FDA’s New Era Signals Dramatic Shift in Drug Development - macnifico.pt
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now? - The Globe and Mail
Recursion Pharma rises, Intel & Five Below fall: Trending Tickers - Yahoo Finance
Recursion: FDA To Replace Animal Testing With AI?A Small But Necessary Win - Seeking Alpha
Recursion (RXRX) Utilizes AI for Enhanced Drug Discovery - GuruFocus
The AI Revolution in Biotech: Recursion Pharmaceuticals Soars 19.18% on FDA's New Approach to Animal Testing - RagingBull
Recursion Pharmaceuticals Shares Are Up Today: what's Going On? - Benzinga
Nvidia-Backed Recursion Pharma Soars After-Hours As FDA Eyes AI Over Animal Testing For Drugs: Retail Traders Elated - MSN
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study - Zacks Investment Research
Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform - TipRanks
0.78%
2.03%
자본화:
|
볼륨(24시간):